Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has spent years building a highly profitable cystic fibrosis franchise. Now, with newer treatments entering the market and its acquisition of Crinetics Pharmaceuticals completed, the company is working to establish additional sources of growth.
The stock closed at $510.08 on October 9, with a forward P/E of 24.10, according to the latest available statistics from Yahoo Finance. That valuation makes the financial contribution from Vertex’s expanding portfolio particularly important. Its established medicines continue generating substantial revenue, but newer products must eventually contribute enough to make diversification meaningful at the company level.
But before we get into the investment story, take a look at our ranking of the best healthcare stocks to buy according to hedge funds. Check out the complete list here for more insight into the sector.
Bull Case
Vertex’s second-quarter results demonstrate the resilience of its core business. Revenue increased 12% year over year to $3.33 billion, prompting management to raise its full-year revenue guidance to $13.1 billion–$13.2 billion. Cystic fibrosis treatments generated $3.21 billion, approximately 96% of quarterly revenue. ALYFTREK was particularly strong, with sales reaching $573.6 million, compared with $156.8 million a year earlier.
The company’s newer medicines are also gaining traction. CASGEVY, its gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia, generated $76 million, increasing 151% year over year and 78% quarter over quarter. JOURNAVX, its non-opioid acute-pain treatment, contributed $50 million, representing 71% quarter-over-quarter sequential growth and more than quadrupling compared to $12 million in the prior year period. We also crafted a list of the 12 Cheap Biotech Stocks to Buy Now through reliable research. Access the complete list here.
Although their sales remain relatively small, both treatments are demonstrating commercial progress. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) expects combined non-cystic fibrosis revenue of at least $500 million in 2026, namely CASGEVY and JOURNAVX. Vertex’s growth ambitions have expanded further following its September acquisition of Crinetics Pharmaceuticals, which has a total equity value of approximately $10 billion.
The transaction adds PALSONIFY, an approved treatment for acromegaly, and investigational treatment atumelnant. Vertex expects the acquisition to become accretive to non-GAAP operating income in 2029, providing a longer-term target against which investors can assess the deal. Keep up with the healthcare sector through our insightful articles covering bull and bear cases. Along with VRTX, read our recently published article on Danaher Has Barely Moved in a Year. Is its 25x Earnings Valuation Justified?
Bear Case
The biggest question for investors at the present is how quickly diversification can become financially meaningful. Despite strong percentage growth, CASGEVY and JOURNAVX contributed only $126 million in combined second-quarter revenue, compared with $3.21 billion from cystic fibrosis treatments.
Even management’s full-year expectation of at least $500 million in non-CF revenue would represent less than 4% of its $13.1 billion–$13.2 billion total revenue guidance, if achieved at that minimum level. That leaves Vertex’s earnings heavily dependent on its established franchise while the company invests in expanding newer businesses.
For more insight into how investment stories for other popular healthcare stocks compare with one another, take a look at our insightful article on Danaher vs. Medtronic: Which Healthcare Recovery Story Has More Upside?.
Coming back to the investment case, profit growth also deserves attention for VRTX. The company reported that second-quarter non-GAAP EPS increased to $4.73 from $4.52, approximately 5%, considerably slower than revenue growth of 12%. The company attributed the relatively modest increase in non-GAAP net income to higher operating expenses that partially offset revenue growth. These expenses include commercial investments supporting JOURNAVX and preparations for its renal-disease portfolio.
Crinetics introduces another financial consideration. Vertex paid approximately $8.8 billion net of estimated acquired cash, and management’s expected operating-income accretion does not begin until 2029. The company has not yet reported the acquisition’s full impact on its post-transaction earnings.
What Does the Valuation Reveal?
Vertex’s cystic fibrosis franchise continues supporting strong revenue and profitability, while newer medicines are showing measurable commercial progress.
However, its valuation is not supported by rapid near-term earnings growth alone. The company is investing heavily in businesses whose revenue contributions remain relatively small. The financial question is whether those investments can eventually deliver meaningful earnings beyond cystic fibrosis. Vertex’s next results will provide another opportunity to assess that transition, particularly following the Crinetics acquisition.
For now, the data points to Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) as a profitable company with expanding growth opportunities, but one whose diversification remains considerably more advanced strategically than financially.
While we acknowledge the risk and potential of VRTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than VRTX and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race? AND Abbott vs. Intuitive Surgical: Is Consistent Growth Better Than Premium Growth?
This article is originally published at Insider Monkey.
Hedge Fund Resource Center